Clinical Trial Update: Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the efficacy and safety of ELND005 for agitation and aggression in Alzheimer's disease; study completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ELND005

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-08-15